CJC-1295 laboratory research investigates a synthetic 30-amino acid growth hormone-releasing hormone (GHRH) analog designed to stimulate pituitary somatotrophs. Studied as a long-acting GHRH secretagogue, CJC-1295 sustains growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1) levels for tissue repair research and cellular proliferation models without disrupting basal pulsatile secretion patterns.
CJC-1295 laboratory research investigates a synthetic 30-amino acid growth hormone-releasing hormone (GHRH) analog designed to stimulate pituitary somatotrophs. Studied as a long-acting GHRH secretagogue, CJC-1295 sustains growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1) levels for tissue repair research and cellular proliferation models without disrupting basal pulsatile secretion patterns.
CJC-1295 is a synthetic peptide modification of human growth hormone-releasing hormone (GHRH 1-29), optimized to extend biological half-life and enhance receptor binding affinity. In laboratory environments, researchers utilize this compound to analyze pituitary somatotroph receptor kinetics, intracellular signal transduction pathways, and downstream anabolic signaling events.
As a primary tool within growth hormone secretagogues research, CJC-1295 allows investigators to evaluate how sustained receptor occupation alters gene expression related to cellular repair, protein synthesis, and metabolic homeostasis. Preclinical models rely on high-purity synthesized peptides to yield reproducible, high-fidelity data across repeated assay trials.
Native GHRH (1-29) undergoes rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) in biological matrices, limiting its operational window in experimental models. CJC-1295 addresses this kinetic limitation through selective amino acid substitutions at positions 2, 8, 15, and 27, which resist enzymatic degradation while preserving GHRH receptor binding efficacy.
Investigators categorize CJC-1295 into two distinct chemical variants: CJC-1295 without Drug Affinity Complex (No DAC, also known as modified GRF 1-29) and CJC-1295 with DAC. The addition of the Drug Affinity Complex introduces a maleimido-propionic acid linker that covalently binds to circulating serum albumin in vivo or in serum-containing media. This bioconjugation significantly expands the molecular mass and slows renal clearance, extending the compound's terminal half-life from minutes to several days in animal models.
At the cellular level, CJC-1295 functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a G-protein-coupled receptor predominantly localized on anterior pituitary somatotrophs. Ligand binding activates the Gs alpha subunit, stimulating transmembrane adenylyl cyclase to convert ATP into cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP concentrations subsequently activate protein kinase A (PKA), triggering voltage-gated calcium influx and secretagogue release.
Preclinical studies demonstrate that prolonged activation of this pathway induces systemic release of endogenously produced growth hormone. Subsequently, systemic GH binds to hepatic growth hormone receptors, upregulating the transcription and secretion of insulin-like growth factor 1 (IGF-1). Downstream, IGF-1 mediates cellular proliferation, extracellular matrix remodeling, and anti-apoptotic cascades in diverse experimental tissues. Detailed kinetic evaluations are compiled within the PX1 Research library.
In animal models, CJC-1295 administration has been extensively evaluated for its influence on soft tissue regeneration, wound healing velocity, and skeletal muscle hypertrophy. Rodent models receiving CJC-1295 exhibit increased nitrogen retention, accelerated collagen deposition in skin flap models, and elevated myofibrillar protein synthesis via downstream mTOR pathway activation.
Furthermore, in vitro assays using primary chondrocytes and osteoblasts reveal that sustained IGF-1 transcription triggered by CJC-1295 stimulation enhances extracellular matrix mineralization and glycosaminoglycan synthesis. These findings position the CJC-1295 research peptide as a critical reference agent for studying physiological repair mechanisms under controlled laboratory conditions.
When designing somatotropic research assays, principal investigators frequently compare CJC-1295 against other GHRH receptor ligands and secretagogues to establish baseline performance metrics. While Sermorelin preclinical review models examine the native 29-amino acid sequence with rapid clearance dynamics, CJC-1295 provides a modified structure optimized for extended signaling duration.
Additionally, CJC-1295 is frequently evaluated alongside non-GHRH secretagogues such as ghrelin mimetics. For instance, Ipamorelin research overview assays assess selective growth hormone secretagogue receptor (GHSR-1a) activation, whereas Tesamorelin laboratory overview focuses on lipolytic mechanisms using a distinct trans-3-hexenoic acid derivative of GHRH. Combining GHRH analogs like CJC-1295 with GHSR agonists often demonstrates synergistic signaling amplification in isolated somatotroph culture systems.
To preserve peptide integrity during in vitro assays, lyophilized CJC-1295 must be reconstituted using precise laboratory protocols. Researchers typically utilize Bacteriostatic Water (0.9% benzyl alcohol) for multi-use laboratory bench work or Sterile Normal Saline (0.9% NaCl) for immediate cellular culture addition.
Reconstitution should be performed by gently introducing the solvent along the internal glass wall of the vial, avoiding direct high-pressure impaction onto the lyophilized cake. Gentle swirly rotation is recommended; vigorous agitation or vortexing must be strictly avoided to prevent mechanical shearing of the secondary peptide structure. Following complete dissolution, working solutions should be aliquoted to minimize freeze-thaw degradation cycles.
Lyophilized CJC-1295 exhibits high stability when stored in temperature-controlled desiccated environments. For long-term storage prior to reconstitution, vials should be maintained at -20°C or -80°C, shielded from ambient light Exposure. Under these conditions, structural integrity is preserved across extended research timelines.
Once reconstituted into aqueous solution, CJC-1295 demonstrates temperature-dependent degradation rates. Refrigerated storage at 2°C to 8°C preserves bioactivity for short experimental windows, whereas reconstituted aliquots intended for extended study require storage at -80°C. Repeated temperature fluctuations induce oxidation of methionine residues and cleavage of amide bonds, which can compromise quantitative binding assays.
Assay reproducibility relies entirely on chemical purity and raw material consistency. High-Performance Liquid Chromatography (HPLC) is employed to verify peptide purity levels, ensuring the sample exceeds 99% structural homogeneity without truncated synthesis side-products. Concurrently, Mass Spectrometry (MS) validates exact molecular mass against theoretical sequence weight.
For cellular assays and animal models, bacterial endotoxins introduce confounding inflammatory variables that compromise scientific control. Analytical certification must confirm endotoxin levels fall below strict safety thresholds (typically <0.01 EU/μg). Researchers can acquire fully validated, endotoxin-tested research reagents with lot-specific documentation directly for institutional projects.
PX1 Research maintains rigorous analytical and manufacturing compliance to support demanding academic and industrial scientific research. Every batch of CJC-1295 is synthesized in USA-based, GMP-compliant facilities adhering to strict quality control protocols.
Independent verification is performed by ISO 17025 accredited analytical laboratories. Every lot includes a comprehensive Certificate of Analysis (COA) detailing RP-HPLC purity profiles, mass spectrometry verification, mass balance analysis, and quantitative endotoxin testing. Institutional laboratories seeking high-volume reagents can apply for a specialized bulk research account to streamline procurement.
CJC-1295 is designated strictly for in vitro, biochemical, and animal laboratory research purposes. It is not approved for human or veterinary medical applications, diagnostic procedures, or therapeutic intervention. Institutional researchers must handle this compound utilizing standard Good Laboratory Practices (GLP).
Appropriate Personal Protective Equipment (PPE)—including nitrile gloves, lab coats, and safety eyewear—must be utilized during handling and reconstitution. All waste materials, including single-use vials and reconstituted media, must be disposed of in compliance with local biosafety and chemical disposal regulations.
What is the primary biological target of CJC-1295 in laboratory research?
CJC-1295 targets the growth hormone-releasing hormone receptor (GHRH-R) on pituitary somatotrophs, stimulating intracellular cAMP accumulation and downstream growth hormone release.
What is the key structural difference between CJC-1295 with DAC and No DAC?
CJC-1295 with DAC includes a maleimido-propionic acid linker that covalently binds to serum albumin, extending half-life to several days in vivo. CJC-1295 No DAC lacks this linker and possesses a much shorter half-life.
How should CJC-1295 be stored upon receipt in the laboratory?
Lyophilized CJC-1295 should be stored at -20°C or -80°C in a desiccated container away from light. Reconstituted solutions should be stored at 2°C to 8°C for short-term use or aliquoted and stored at -80°C.
What solvent is recommended for reconstituting CJC-1295 for in vitro assays?
Laboratory Grade Bacteriostatic Water or Sterile 0.9% Normal Saline are standard solvents depending on whether the experimental setup requires single-use or multi-use protocols.
How does PX1 Research verify the purity of CJC-1295?
PX1 Research utilizes ISO 17025 accredited third-party laboratories to perform RP-HPLC (purity >99%), Mass Spectrometry (identity validation), and chromogenic LAL assays (endotoxin testing) for every production lot.
Why is endotoxin testing critical for CJC-1295 laboratory samples?
Bacterial endotoxins trigger inflammatory responses in cellular cultures and rodent models, causing confounding physiological responses that undermine experimental data validity.
What downstream biological marker is most commonly measured alongside GH elevation in CJC-1295 studies?
Insulin-like Growth Factor 1 (IGF-1) is the primary downstream biomarker quantified in serum or culture media to measure the prolonged biological effect of CJC-1295.
Can CJC-1295 be combined with other growth hormone secretagogues in research protocols?
Yes, preclinical studies frequently combine GHRH analogs like CJC-1295 with GHSR mimetics like Ipamorelin to investigate additive or synergistic pituitary GH release mechanisms.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.